Study OAS ·
FDI Surge in India's Pharma Sector
Overview & Key Figures:
- Total FDI Inflow:
- The pharmaceutical and medical devices sector witnessed a robust foreign investment inflow, with total FDI reaching approximately Rs 19,134.4 crore during the financial year 2024-25.
- Breakdown of Investment:
- Rs 11,888 crore was invested from April to December in the last fiscal.
- An additional 13 brownfield FDI proposals worth about Rs 7,246.40 crore were approved, contributing to the overall sum.
Policy Initiatives & Government Schemes:
- Production Linked Incentive (PLI) Scheme:
- A key driver behind this investment surge, the PLI scheme for pharmaceuticals has significantly boosted domestic manufacturing.
- The scheme aims to:
- Attract investments,
- Reduce import dependency,
- Enhance exports, and
- Strengthen India's global manufacturing base.
- Exceeding Targets:
- Originally committed investments under the PLI scheme have surpassed targets, with realized investments already exceeding the initial commitments—indicative of the scheme’s success in attracting FDI.
Notable Projects & Sectoral Impact:
- Originally committed investments under the PLI scheme have surpassed targets, with realized investments already exceeding the initial commitments—indicative of the scheme’s success in attracting FDI.
- Bulk Drugs PLI Scheme:
- Under this initiative, a total of 48 projects have been selected, with 34 projects already commissioned for the production of 25 essential bulk drugs.
- Key Projects Include:
- Penicillin G Project (Kakinada, Andhra Pradesh):
- Investment of approximately Rs 1,910 crore,
- Expected to substitute imports worth around Rs 2,700 crore per annum.
- Clavulanic Acid Project (Nalagarh, Himachal Pradesh):
- Carries an investment of about Rs 450 crore,
- Anticipated to offer significant import substitution benefits.
- Penicillin G Project (Kakinada, Andhra Pradesh):
- Overall Industry Transformation:
- The inflow of FDI not only catalyzes upgrade of domestic production capabilities but also positions India as a competitive hub in the global pharmaceutical value chain.